Journal of Thrombosis and Thrombolysis

, Volume 27, Issue 4, pp 461–464 | Cite as

Warfarin in vulnerable older adults with atrial fibrillation



  1. 1.
    Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347(13):969–974. doi:10.1056/NEJMoa020496 PubMedCrossRefGoogle Scholar
  2. 2.
    Becker RC (2002) Antithrombotic therapy after myocardial infarction. N Engl J Med 347(13):1019–1022. doi:10.1056/NEJMe020097 PubMedCrossRefGoogle Scholar
  3. 3.
    Friedman PA, Rosenberg RD, Hauschka PV, Fitz-James A (1977) A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 494(1):271–276PubMedGoogle Scholar
  4. 4.
    Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18):2370–2375. doi:10.1001/jama.285.18.2370 PubMedCrossRefGoogle Scholar
  5. 5.
    Lee PG, Cigolle C, Blaum C (2009) The co-occurrence of chronic diseases and geriatric syndromes: the health and retirement study. J Am Geriatr Soc 57(3):511–516. doi:10.1111/j.1532-5415.2008.02150.x PubMedCrossRefGoogle Scholar
  6. 6.
    Fairhall N, Aggar C, Kurrle SE et al (2008) Frailty Intervention Trial (FIT). BMC Geriatr 8:27. doi:10.1186/1471-2318-8-27 PubMedCrossRefGoogle Scholar
  7. 7.
    Min LC, Elliott MN, Wenger NS, Saliba D (2006) Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J Am Geriatr Soc 54(3):507–511. doi:10.1111/j.1532-5415.2005.00615.x PubMedCrossRefGoogle Scholar
  8. 8.
    Saliba D, Elliott M, Rubenstein LZ et al (2001) The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49(12):1691–1699. doi:10.1046/j.1532-5415.2001.49281.x PubMedCrossRefGoogle Scholar
  9. 9.
    Wenger NS, Solomon DH, Roth CP et al (2003) The quality of medical care provided to vulnerable community-dwelling older patients. Ann Intern Med 139(9):740–747PubMedGoogle Scholar
  10. 10.
    Gharacholou SM, Becker RC (2009) Hemostasis and thrombosis in older adults. J Thromb Thrombolysis 27(2):249–251. doi:10.1007/s11239-009-0308-4 PubMedCrossRefGoogle Scholar
  11. 11.
    The ACTIVE Investigators (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360:1–13CrossRefGoogle Scholar
  12. 12.
    Aguilar MI, Hart R (2008) Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no history of stroke or transient ischemic attacks. Stroke 39:1399–1400CrossRefGoogle Scholar
  13. 13.
    Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154(13):1449–1457. doi:10.1001/archinte.154.13.1449
  14. 14.
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22):2864–2870. doi:10.1001/jama.285.22.2864 PubMedCrossRefGoogle Scholar
  15. 15.
    American Geriatrics Society Clinical Practice Committee (2002) The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline. J Am Geriatr Soc 50(8):1439–1445; discussion 1446–1447. doi:10.1046/j.1532-5415.2002.50380.x Google Scholar
  16. 16.
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):160S–198S. doi:10.1378/chest.08-0670 PubMedCrossRefGoogle Scholar
  17. 17.
    Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696. doi:10.1161/CIRCULATIONAHA.106.653048 PubMedCrossRefGoogle Scholar
  18. 18.
    Poli D, Antonucci E, Marcucci R et al (2007) Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 121(3):347–352. doi:10.1016/j.thromres.2007.05.014 PubMedCrossRefGoogle Scholar
  19. 19.
    Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86Google Scholar
  20. 20.
    Gage BF, Yan Y, Milligan PE et al (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151(3):713–719. doi:10.1016/j.ahj.2005.04.017 PubMedCrossRefGoogle Scholar
  21. 21.
    Boult C, Boult LB, Morishita L, Dowd B, Kane RL, Urdangarin CF (2001) A randomized clinical trial of outpatient geriatric evaluation and management. J Am Geriatr Soc 49(4):351–359. doi:10.1046/j.1532-5415.2001.49076.x PubMedCrossRefGoogle Scholar
  22. 22.
    Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW (2005) Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 118(6):612–617. doi:10.1016/j.amjmed.2005.02.022 PubMedCrossRefGoogle Scholar
  23. 23.
    Aquilante CL, Langaee TY, Lopez LM et al (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79(4):291–302. doi:10.1016/j.clpt.2005.11.011 PubMedCrossRefGoogle Scholar
  24. 24.
    Klein TE, Altman RB, Eriksson N et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753–764. doi:10.1056/NEJMoa0809329 PubMedCrossRefGoogle Scholar
  25. 25.
    Turpie AG (2008) New oral anticoagulants in atrial fibrillation. Eur Heart J 29(2):155–165. doi:10.1093/eurheartj/ehm575 PubMedCrossRefGoogle Scholar
  26. 26.
    A study comparing once daily oral Rivaroxaban with adjusted-dose oral warfarin for the prevention of stroke in subjects with non-valvular atrial fibrillation (ROCKET-AF).
  27. 27.
    Apixaban for the prevention of stroke in subjects with atrial fibrillation (ARISTOTLE).

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of CardiologyDuke University Medical Center and Duke Clinical Research InstituteDurhamUSA
  2. 2.Division of GeriatricsDuke University Medical Center and Duke Clinical Research InstituteDurhamUSA
  3. 3.Duke Clinical Research InstituteDurhamUSA

Personalised recommendations